Home > Oncology > ASCO 2019 > Gastrointestinal Cancers > FOLFOXIRI plus bevacizumab an option for patients with mCRC and poor prognosis

FOLFOXIRI plus bevacizumab an option for patients with mCRC and poor prognosis

Presented By
Dr Javier Sastre, Hospital ClĂ­nico San Carlos, Spain
Conference
ASCO 2019
Trial
Phase 3, VISNU-1
Medical writer: Debra Gordon FOLFOXIRI plus bevacizumab improves progression-free survival (PFS) by about 3 months compared to FOLFOX plus bevacizumab in patients with first-line metastatic colorectal cancer (mCRC) and a poor prognosis, albeit with a higher rate of serious side effects, according to the results of the phase III VISNU-1 trial (Abstract 3507) reported during the Gastrointestinal (Colorectal) Cancer Oral Abstract Session on June 1. VISNU-1 is the first mCRC study performed in a population selected by baseline circulating tumour cell (CTC) count. Although FOLFOXIRI plus bevacizumab has a demonstrated PFS and overall survival (OS) benefit compared with FOLFOX plus bevacizumab, this schedule is not routinely recommended in all patient groups because of toxicity, lead author Javier Sastre, MD, PhD, of Hospital Clínico San Carlos, Spain, said. “We considered that it would be of interest to explore the role of this combination in a sub...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on